MetaCap

Addex Therapeutics (ADXN) vs Tempest Therapeutics (TPST)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Addex Therapeutics is the larger company by market cap ($6.1 million vs $5.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ADXN+10.86%TPST-63.74%
+76%+3%-70%
Oct 7, 20261 yearNov 20, 2026
ADXN+7.81%TPST-62.24%
+31%-18%-67%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ADXN versus TPST key metrics
MetricADXNTPST
Share price$3.47$0.287
Market cap$6.08M$5.74M
1-day change+2.06%-6.18%
YTD return—-90.00%
1-year return—-91.80%
5-year return—-99.77%
EPS (TTM)$-7.56$-3.16
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-26.26M
52-week high$10.43$4.22
52-week low$2.56$0.28
Distance from 52-week high-66.73%-93.20%
Analyst consensus—strong_buy
Avg. price target upside—+2339.02%
Average volume383.35K2.56M
Shares outstanding1.75M20.00M
Employees34
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Addex Therapeutics

ADXN stock →

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes.

Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees

About Tempest Therapeutics

TPST stock →

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

ADXN vs TPST FAQ

Which is bigger, Addex Therapeutics or Tempest Therapeutics?

Addex Therapeutics (ADXN) is larger, with a market capitalization of $6.08M compared with $5.74M for Tempest Therapeutics (TPST).

Are Addex Therapeutics and Tempest Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons